• Explore /
  • Poster
  • / Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy?

Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy?

Abstract Poster

Authors

null

Ravi Kumar Paluri

Wake Forest Baptist Health, Winston-Salem, NC

Ravi Kumar Paluri , Michelle Silver , Paul Cockrum , Syvart Dennen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 630)

DOI

10.1200/JCO.2024.42.3_suppl.630

Abstract #

630

Poster Bd #

J17

Abstract Disclosures

Similar Posters

First Author: Julien Taieb

Poster

2017 Gastrointestinal Cancers Symposium

Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).

Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).

First Author: Hui-Li Wong

First Author: Ramesh K. Ramanathan

First Author: Syvart Dennen